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Infection of mice with murine gammaherpesvirus 68 (MHV-68) is a well-characterized small animal model
for the study of gammaherpesvirus infection. MHV-68 belongs to the same herpesvirus family as herpesvirus
saimiri (HVS) of New World squirrel monkeys and human herpesvirus 8 (HHV-8) (also referred to as Kaposi’s
sarcoma-associated herpesvirus [KSHV]). The open reading frame ORF74 of HVS, KSHV, and MHV-68
encodes a protein with homology to G protein-coupled receptors and chemokine receptors in particular. ORF74
of KSHV (human ORF74 [hORF74]) is highly constitutively active and has been implicated in the pathogen-
esis of Kaposi’s sarcoma. MHV-68-encoded ORF74 (mORF74) is oncogenic and has been implicated in viral
replication and reactivation from latency. Here, we show that mORF74 is a functional chemokine receptor.
Chemokines with an N-terminal glutamic acid-leucine-arginine (ELR) motif (e.g., KC and macrophage in-
flammatory protein 2) act as agonists on mORF74, activating phospholipase C, NF-B, p44/p42 mitogen-
activated protein kinase, and Akt signaling pathways and inhibiting formation of cyclic AMP. Using 125I-
labeled CXCL1/growth-related oncogene  as a tracer, we show that murine CXCL10/gamma interferon-
inducible protein 10 binds mORF74, and functional assays show that it behaves as an antagonist for this virally
encoded G protein-coupled receptor. Profound differences in the upstream activation of signal transduction
pathways between mORF74 and hORF74 were found. Moreover, in contrast to hORF74, no constitutive activity
of mORF74 could be detected.
Murid herpesvirus 4 strain 68 (MHV-68) belongs to the
same family of herpesviruses as the prototype gamma-2-her-
pesvirus herpesvirus saimiri (HVS) and human Kaposi’s sar-
coma (KS)-associated herpesvirus (KSHV) (also called human
herpesvirus 8 [HHV-8]) and is genetically related to the human
gamma-1-herpesvirus Epstein-Barr virus (EBV) (13, 44). Her-
pesviruses establish a lifelong infection of the host, are in-
volved in lymphoproliferative diseases, and are associated with
several types of tumors. For example, EBV is associated with
Burkitt’s lymphoma (32), and KSHV is found in virtually all
cases of KS, which is the most common AIDS-related malig-
nancy (11). KSHV and EBV are highly species-specific viruses,
for which no fully permissive cell lines or animal models are
available. In contrast, MHV-68 readily infects a variety of cell
lines (25) and laboratory mice (29). Therefore, MHV-68 has
been widely adopted as a model for the study of gammaher-
pesviruses.
Infection of murid rodents with MHV-68 via the respiratory
system leads to lytic infection of lung epithelial cells followed
by latent infection in these cells (41); in the spleens of these
rodents, mainly B lymphocytes, but also macrophages and den-
dritic cells, are infected (14, 42, 43, 47). Early after infection, a
splenomegaly characterized by a transient expansion of mono-
nuclear cells is observed, followed by a peripheral infectious
mononucleosis-like syndrome. Extended periods of infection
are characterized by the development of a lymphoproliferative
disease in about 10% of the mice (29).
All members of the gamma-2-herpesvirus family encode ho-
mologs of cellular proteins. Several of these homologs have
retained their cellular functions and properties and are likely
to interfere with cellular events. Among these proteins is
ORF74, encoded by, for example, HVS (30), KSHV (8), and
MHV-68 (44, 45), which shows homology to human chemokine
receptors and to CXCR2 in particular. ORF74 encoded by
KSHV (human ORF74 [hORF74]) has gained a lot of interest,
since this viral G protein-coupled receptor (vGPCR) is consti-
tutively active and can be positively and negatively regulated by
endogenous chemokines (2, 16–18, 34). Initially, hORF74 was
shown to transform NIH 3T3 cells and to be tumorigenic when
these cells were injected into nude mice (2, 3). Moreover,
transgenic mice expressing hORF74 under the control of hu-
man CD2 promoter or simian virus 40 early promoter develop
angioproliferative lesions in multiple organs that morphologi-
cally resemble KS lesions (21, 49). This tumorigenic property
appears to be a function of both constitutive signaling and
regulation by chemokines (22). Similarly, transgenic mice ex-
pressing hORF74 exclusively in endothelial cells developed
symptoms closely resembling KS, implicating hORF74 in the
initiation of KSHV-induced tumor development (26).
At the moment, little is known about ORF74 encoded by
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MHV-68 (mORF74). mORF74 shows 23% identity with
hORF74 (44). In contrast to hORF74, which has been charac-
terized as a lytic gene (9, 23), mORF74 shows early-late, la-
tency-associated expression kinetics, with minimal transcrip-
tion in lytically infected cells (12, 33, 45). mORF74 has been
shown to be involved in viral replication and reactivation of
MHV-68 from latency (24, 28). Similar to hORF74, mORF74
was recently shown to transform NIH 3T3 cells (45), suggesting
that mORF74 might also act as a constitutively active chemo-
kine receptor. However, so far, no details on the ligand binding
characteristics or intracellular signaling have been reported for
mORF74.
In this study, we show that mORF74, in contrast to hORF74,
is not constitutively signaling in transiently transfected COS-7
cells. However, upon stimulation with a distinct subset of che-
mokines, mORF74 activates phospholipase C (PLC), p44/p42
mitogen-activated protein kinase (MAPK), Akt, and to a lesser
extent, NF-B, and inhibits cyclic AMP (cAMP) formation.
Additionally, we identify murine gamma interferon inducible
protein 10 (IP-10) as an antagonist and show that 125I-labeled
CXCL1/growth-related oncogene  (GRO) can be used as a
radioligand for this virally encoded GPCR.
MATERIALS AND METHODS
Materials. Chloroquine diphosphate, DEAE-dextran (chloride form), o-phen-
ylenediamine (OPD), and pertussis toxin (PTX) were obtained from Sigma (St.
Louis, Mo.). Bovine serum albumin fraction V (BSA) and Nonidet P-40 were
obtained from Roche (Mannheim, Germany). D-Luciferin was purchased from
Duchefa Biochemie B.V. (Haarlem, The Netherlands). Cell culture media, pen-
icillin, and streptomycin were obtained from Life Technologies (Gaithersburg,
Md.), and fetal bovine serum was purchased from Integro B.V. (Dieren, The
Netherlands). [myo-2-3H]inositol (17 Ci/mmol) and 125I-labeled CXCL1/GRO
(2,200 Ci/mmol) were obtained from Perkin-Elmer Life Sciences (Boston,
Mass.). CXCL11/IP-9 was purchased from R&D Systems, Inc. (Minneapolis,
Minn.), and other chemokines were obtained from PeproTech (Rocky Hill, N.J.).
DNA constructs. The cDNA containing MHV-68-encoded ORF74 has been
previously described (45) and was subcloned into pcDEF3 (a gift from J.A.
Langer) (19). mORF74 was tagged at the N terminus with the influenza virus
hemagglutinin (HA) epitope (HA-mORF74) using PCR. The cDNA of the
HHV-8-encoded ORF74 (GenBank accession number U71368 with a silent
G3T mutation at position 927) was a gift from T. Schwartz and inserted in
pcDEF3 after PCR amplification. The reporter plasmid pNF-B-Luc was ob-
tained from Stratagene (La Jolla, Calif.), and pTLNC-21CRE was obtained from
W. Born.
Cell culture and transfection. COS-7 cells were grown at 5% CO2 at 37°C in
Dulbecco’s modified Eagle’s medium supplemented with 5% fetal bovine serum,
50 IU of penicillin per ml, and 50 mg of streptomycin per ml. COS-7 cells were
transiently transfected using DEAE-dextran (106 cells per indicated amount of
cDNA). The total amount of cDNA transfected per experiment was kept con-
stant by the addition of the empty vector (pcDEF3).
Enzyme-linked immunosorbent assay (ELISA). Transfected COS-7 cells were
seeded in 48-well plates (Costar). Forty-eight hours after transfection, cells were
washed with Tris-buffered saline (TBS), fixed with 4% paraformaldehyde in
phosphate-buffered saline (PBS), and permeabilized with 0.5% Nonidet P-40 in
TBS where indicated. After the cells were blocked with 1% skim milk in 0.1 M
NaHCO3 (pH 8.6) for 4 h at room temperature, they were incubated overnight
at 4°C with mouse monoclonal anti-HA antibody (a gift from J. van Minnen) in
TBS containing 0.1% BSA. Cells were washed three times with TBS and incu-
bated for 2 h at room temperature with goat anti-mouse horseradish peroxidase-
conjugated secondary antibody (Bio-Rad). Subsequently, cells were incubated
with 150 l of OPD substrate solution (2.2 mM OPD, 35 mM citric acid, 66 mM
Na2HPO4, 0.015% H2O2 [pH 5.6]). The reaction was stopped with 75 l of 1 M
H2SO4, and absorption at 490 nm was determined.
[3H]inositol phosphate production. Transfected COS-7 cells were seeded in
24-well plates (Costar), and 24 h after transfection, they were labeled overnight
in Earle’s inositol-free minimal essential medium supplemented with [myo-2-
3H]inositol (1 Ci/ml) in the presence or absence of PTX (100 ng/ml). Subse-
quently, the medium was aspirated, and cells were washed for 10 min with
Dulbecco’s modified Eagle’s medium containing 25 mM HEPES (pH 7.4) and 20
mM LiCl and incubated for 2 h in the same medium in the presence or absence
of the indicated chemokines. The incubation was stopped by aspiration of the
medium and addition of ice-cold 10 mM formic acid. After incubation on ice for
90 min, inositol phosphates were isolated by anion-exchange chromatography
(Dowex AG1-X8 columns; Bio-Rad) and counted by liquid scintillation.
Reporter gene assays. COS-7 cells were transfected with pNF-B-Luc (NF-B
assay) or pTLNC-21CRE (cAMP-responsive element [CRE] assay), and indi-
cated plasmids. Transfected cells were seeded in 96-well white plates (Costar) in
serum-free culture medium in the presence or absence of PTX (100 ng/ml). For
the NF-B assay, the cells were incubated with the indicated chemokines for
48 h, after which NF-B-driven luciferase (Luc) expression was measured by
aspiration of the medium and addition of 25 l of luciferase assay reagent (0.83
mM ATP, 0.83 mM D-luciferin, 18.7 mM MgCl2, 0.78 M Na2H2P2O7, 38.9 mM
Tris [pH 7.8], 0.39% [vol/vol] glycerol, 0.03% [vol/vol] Triton X-100, 2.6 M
dithiothreitol). Luminescence was measured for 3 s in a Wallac Victor2 instru-
ment. For the CRE assay, the indicated chemokines were added together with
forskolin (105 M) 18 h after transfection, and cells were assayed for lumines-
cence 24 h after transfection as described above.
Western blot analysis. Transfected COS-7 cells were seeded in 12-well plates
(Costar). Forty-eight hours after transfection, cells were stimulated with chemo-
kines (107 M, 5 min) and lysed in radioimmunoprecipitation assay buffer (phos-
phate-buffered saline containing 1% Nonidet P-40, 0.1% sodium dodecyl sulfate,
0.5% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium
orthovanadate, 2 g of aprotinin per ml, 2 g of leupeptin per ml), sonicated,
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and
blotted onto a polyvinylidene difluoride membrane. Antibodies recognizing
p44/42 MAPK, Akt, and phospho-Akt (S473) (New England Biolabs, Inc., Bev-
erly, Mass.) were used in combination with a goat anti-rabbit horseradish per-
oxidase-conjugated secondary antibody (Bio-Rad). The antibody recognizing
phospho-p44/42 MAPK (T202/Y204) (New England Biolabs, Inc.) was used in
combination with a goat anti-mouse horseradish peroxidase-conjugated second-
ary antibody (Bio-Rad). Protein bands were detected by an enhanced-chemilu-
minescence assay and directly quantified with an Image station (NEN Life
Science Products, Inc., Boston, Mass.).
Binding experiments. Transfected COS-7 cells were seeded in 48-well plates.
Forty-eight hours after transfection, binding was performed on whole cells for 4 h
at 4°C using 125I-labeled CXCL1/GRO (approximately 80 pM) in binding buffer
(50 mM HEPES [pH 7.4], 1 mM CaCl2, 5 mM MgCl2, 0.5% BSA) containing
increasing concentrations of unlabeled chemokine. After incubation, cells were
washed three times with ice-cold binding buffer supplemented with 0.5 M NaCl.
Subsequently, cells were lysed and counted in a Wallac Compugamma counter.
RESULTS
Expression of mORF74 in COS-7 cells. To determine
whether mORF74 was expressed at the cell surface of tran-
siently transfected COS-7 cells, mORF74 was tagged with the
influenza virus HA epitope. Transfection of COS-7 cells with
increasing amounts of cDNA encoding HA-mORF74 resulted
in increased cell surface and intracellular expression of HA-
mORF74 as determined by an ELISA with a mouse monoclo-
nal anti-HA antibody (Fig. 1). HA-mORF74 was mainly ex-
pressed on the cell surface (nonpermeabilized cells), whereas a
considerable proportion of HA-hORF74 was also found inside
the cells (permeabilized cells). Since transfection of 2 g of
cDNA encoding HA-mORF74 resulted in a cell surface ex-
pression level comparable to the level with transfection of 2 g
of the cDNA encoding HA-hORF74, further experiments were
performed using 2 g of cDNA encoding mORF74 per 106
COS-7 cells unless indicated otherwise.
Comparison of constitutive signaling capacities of mORF74
and hORF74. (i) PLC activation. hORF74 has been shown to
constitutively activate a variety of signal transduction path-
ways, including inositol phosphate (InsP) formation through
activation of PLC (2, 34, 38). Transient transfection of COS-7
cells with increasing amounts of cDNA encoding mORF74 did
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not result in an increase of InsP (Fig. 2A), whereas in the same
set of experiments, hORF74 expression constitutively en-
hanced InsP production via a PTX-insensitive pathway (Fig.
2A, insert).
(ii) NF-B activation. Constitutive activation of the tran-
scription factor NF-B by hORF74 has also been shown in
several cell lines (6, 10, 27, 31, 36, 37, 39). We used a luciferase
reporter gene with NF-B-responsive elements to determine
whether mORF74 activates NF-B as well. Transfection of
COS-7 cells with increasing amounts of cDNA encoding
mORF74 did not activate NF-B, in contrast to hORF74,
which potently stimulated NF-B-driven luciferase expression
(Fig. 2B). The constitutive signaling of hORF74 was inhibited
for approximately 70% upon PTX treatment (Fig. 2B, insert),
indicating the involvement of Gi proteins as well as PTX-
insensitive G proteins.
(iii) Inhibition of cAMP. Since mORF74 did not show con-
stitutive signaling in the InsP and NF-B pathways, we sought
other pathways that could have been activated in an agonist-
independent manner. Most chemokine receptors signal
through G proteins of the Gi class, which results in an inhibi-
tion of the formation of intracellular cAMP. Consequently, we
studied the inhibition of forskolin-induced cAMP levels using
a reporter gene assay. Expression of increasing amounts of
mORF74 had no effect on forskolin-induced CRE activation.
In contrast, hORF74 constitutively inhibited cAMP formation
(Fig. 2C). As expected, PTX treatment had no significant effect
on mORF74-expressing cells, but it reversed the effect of
hORF74, showing that the inhibition of cAMP formation by
hORF74 is indeed mediated by Gi proteins. mORF74 also did
not modulate CRE activity in the absence of forskolin, whereas
hORF74 inhibited CRE in the absence of forskolin (Fig. 2C,
insert).
Chemokine regulation of mORF74. To explore the ability of
chemokines to activate mORF74, mORF74-expressing COS-7
cells were incubated with a panel of human CXC chemokines
(CXCL1/GRO, CXCL10/IP-10, CXCL11/IP-9, and CXCL8/
interleukin 8 [IL-8]), the murine CXC chemokines KC and
macrophage inflammatory protein (MIP-2), human CC che-
mokines (CCL4/MIP-1, CCL5/RANTES, and CCL11/
eotaxin), the HHV-8-encoded CC chemokine vCCL2/vMIP-II,
and the CX3C chemokine CX3CL1/fractalkine. The effects of
the various chemokines were evaluated in the CRE reporter
gene assay.
All of the CXC chemokines containing the glutamic acid-
leucine-arginine (ELR) motif (CXCL1/GRO, CXCL8/IL-8,
KC, and MIP-2) inhibited forskolin-induced CRE activation in
a PTX-sensitive manner, whereas the other CXC, CC, and
CX3C chemokines had no effect (Fig. 3A). None of the tested
chemokines had an effect on forskolin-induced cAMP levels in
mock-transfected cells (data not shown).
The agonistic properties of the murine chemokines KC and
MIP-2 were further explored, since they are the most relevant,
considering the fact that mORF74 is encoded by a murine
herpesvirus. KC and MIP-2 both inhibited forskolin-induced
CRE activation in a dose-dependent way with pEC50s of 7.6 
0.3 and 7.3 0.5, respectively (pEC50  the negative log of the
drug concentration that provides a response halfway between
baseline and maximum) (Fig. 3B).
Subsequently, we determined the mORF74-mediated effects
of KC and MIP-2 on the activation of PLC and NF-B. Incu-
bation of mORF74-transfected COS-7 cells with KC or MIP-2
resulted in an increase in InsP formation (Fig. 4A). The ago-
nist-induced PLC activation was sensitive to treatment with
PTX, indicative of the involvement of Gi proteins (Fig. 4A).
Activation of mORF74 by KC and MIP-2 resulted in a mod-
erate activation of NF-B (Fig. 4B).
Recently, it was suggested that the p44/p42 MAPK and Akt
signaling pathways were involved in mORF74-mediated repli-
cation of MHV-68, using inhibitors of their upstream kinases
MEK and phosphatidylinositol 3-kinase (24). Previously, we
and others have shown the constitutive activation of p42/p44
MAPK and Akt by hORF74 in COS-7 cells, which can be
positively and negatively regulated by CXCL1/GRO and
CXCL10/IP-10, respectively (27, 38, 40). In agreement with
our findings in other assays, mORF74 did not constitutively
phosphorylate p42/p44 MAPK in COS-7 cells but activated
p42/p44 MAPK when stimulated with KC or MIP-2 (Fig. 4C).
We also did not detect constitutive signaling for mORF74 to
Akt in COS-7 cells, but Akt was activated after incubation with
KC or MIP-2 (Fig. 4D).
Differential signaling of mORF74 and hORF74 upon stim-
ulation. Recently, transgenic mice expressing the wild-type
(WT) hORF74 and mutant hORF74 proteins have been gen-
erated, and several murine chemokines were found to stimu-
late or inhibit the constitutive activity of hORF74 in COS-7
cells (22, 26, 49). In view of these mouse models, we compared
the upstream signal transduction mechanisms of hORF74 with
those of mORF74 upon stimulation with murine chemokines.
MIP-2 has been reported to activate hORF74-mediated InsP
formation in COS-7 cells, whereas KC was found to be inactive
(22). COS-7 cells transfected with hORF74 were incubated
with KC and MIP-2 in the presence or absence of PTX. MIP-2
activated hORF74 as expected, and KC increased InsP pro-
duction to a lesser extent (Fig. 5A). Constitutive InsP forma-
FIG. 1. Expression of HA-tagged mORF74. COS-7 cells were
transfected with increasing amounts (1, 2, and 5 g) of cDNA encod-
ing HA-mORF74, 2 g of cDNA encoding untagged mORF74, or 2 g
of cDNA encoding HA-hORF74. Forty-eight hours after transfection,
vGPCR expression was determined in an ELISA. A representative
experiment performed in triplicate is shown. The experiment was re-
peated two times.
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tion by hORF74 was insensitive to PTX (Fig. 2A and 5A). In
contrast to MIP-2- or KC-induced stimulation of mORF74
(Fig. 4A), the agonist-induced InsP production by hORF74
was insensitive to PTX (Fig. 5A) and thus likely to be mediated
by the Gq/11 class of G proteins. Similar to the findings for
hORF74-mediated InsP production, MIP-2 was more potent
than KC in activating NF-B through hORF74 (Fig. 5B). In-
terestingly, neither KC- nor MIP-2-induced NF-B activation
via hORF74 was sensitive to PTX (Fig. 5B), whereas constitu-
FIG. 2. Absence of constitutive activity of mORF74. (A) Activation
of PLC. COS-7 cells were transfected with increasing amounts of
cDNA encoding mORF74, 2 g of cDNA encoding hORF74, or 5 g
of empty vector (mock). Forty-eight hours after transfection, InsP
accumulation was determined. (Insert) Activation of PLC in the pres-
ence of PTX. COS-7 cells were transfected with 2 g of cDNA encod-
ing vGPCR or empty vector and incubated in the presence or absence
of PTX. Forty-eight hours after transfection, InsP accumulation was
determined. (B) Activation of NF-B. COS-7 cells were transfected
with increasing amounts of cDNA encoding mORF74, 2 g of cDNA
encoding hORF74, or 5 g of empty vector (mock) and 5 g of
pNFB-Luc. Forty-eight hours after transfection, NF-B-driven lucif-
erase expression was determined. (Insert) Activation of NF-B in the
presence of PTX. COS-7 cells were transfected with 2 g of cDNA
encoding vGPCR or empty vector and 5 g of pNFB-Luc and incu-
bated in the presence or absence of PTX. Forty-eight hours after
transfection, NF-B-driven luciferase expression was determined.
(C) Inhibition of cAMP. COS-7 cells were transfected with increasing
amounts of cDNA encoding mORF74, 2 g of cDNA encoding
FIG. 3. Activation of mORF74 by chemokines. (A) mORF74-me-
diated inhibition of cAMP formation. COS-7 cells were transfected
with 2 g of cDNA encoding mORF74 or with 2 g of empty vector
(mock) and 5 g of pTLNC-21CRE and incubated in the presence or
absence of PTX. Eighteen hours after transfection, forskolin (105 M)
and chemokines (107 M) were added. Twenty-four hours after trans-
fection, CRE-driven luciferase expression was determined. (B) Dose-
dependent activation of mORF74 by KC and MIP-2. COS-7 cells were
transfected with 2 g of cDNA encoding mORF74 and 5 g of
pTLNC-21CRE. Eighteen hours after transfection, forskolin (105 M)
and chemokines were added. Twenty-four hours after transfection,
CRE-driven luciferase expression was determined. In both panels, a
representative experiment performed in triplicate is shown. Each ex-
periment was repeated at least two times.
hORF74, or 5 g of empty vector (mock) and 5 g of pTLNC-21CRE
and incubated in the presence or absence of PTX. Eighteen hours after
transfection, forskolin (Fors) (105 M) was added. Twenty-four hours
after transfection, CRE-driven luciferase expression was determined.
(Insert) CRE modulation in the absence of forskolin. In all panels, a
representative experiment performed in triplicate is shown. Each ex-
periment was repeated at least two times.
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tive NF-B activation by hORF74 was PTX sensitive (Fig. 2B
and 5B).
Binding of murine chemokines to mORF74. Since human
CXCL1/GRO acts as an agonist on mORF74 in the CRE
reporter gene assay (Fig. 3A), we used human 125I-labeled
CXCL1/GRO as a radioligand to determine the affinities of
KC and MIP-2 for mORF74. CXCL1/GRO, KC, and MIP-2
all bound mORF74 with high affinity, with pIC50 values of 9.5
 0.02, 9.3  0.1, and 9.1  0.4, respectively (pIC50  the
negative log of the drug concentration that provides an inhi-
bition halfway between maximum and baseline) (Fig. 6A).
Recently, KC and MIP-2 were shown to be involved in
mORF74-mediated viral replication (24). After infection of
NIH 3T3 cells with WT or mORF74 deletion mutants of
MHV-68, no difference was found in viral replication in the
absence of ligands. However, addition of KC or MIP-2 resulted
in an increase in viral replication in cells infected with WT
virus but not with mORF74 deletion mutants, indicating a role
for mORF74 in MHV-68 replication. Interestingly, Crg-2/
mouse IFN-	 (gamma interferon)-inducible protein 10 (mIP-
10) was found to block KC-induced MHV-68 replication in
NIH 3T3 cells, whereas it had no effect when added alone (24).
Both mIP-10 and human CXCL10/IP-10 could displace 125I-
labeled CXCL1/GRO in a dose-dependent manner (Fig. 6B).
mORF74 seems to have been optimized for the recognition of
mIP-10, since this murine chemokine exhibits a higher pIC50
FIG. 4. mORF74-mediated signal transduction. (A) mORF74-mediated activation of PLC by KC and MIP-2. COS-7 cells were transfected with
2 g of cDNA encoding mORF74 and incubated in the presence or absence of PTX. Forty-eight hours after transfection, InsP accumulation was
determined in the presence or absence () of chemokines (107 M). A representative experiment performed in triplicate is shown. (B) mORF74-
mediated activation of NF-B by KC and MIP-2. COS-7 cells were transfected with 2 g of cDNA encoding mORF74 and 5 g of pNFB-Luc
and incubated in the presence or absence () of chemokines (107 M). Forty-eight hours after transfection, NF-B-driven luciferase expression
was determined. A representative experiment performed in triplicate is shown. (C) mORF74-mediated activation of p44/p42 MAPK by KC and
MIP-2. COS-7 cells were transfected with 2 g of cDNA encoding mORF74 or 2 g of empty vector. Forty-eight hours after transfection, cells
were stimulated with chemokine (107 M) (5 min), and phosphorylation of p44/p42 MAPK was determined by Western blot analysis using specific
anti-phospho-p44/p42 MAPK (P-p44/p42) antibodies. Phosphorylation was quantified by chemiluminescence and corrected for total MAPK
(T-p44/p42) expression on stripped blots. Data are presented as fold increase over control values (mock-transfected cells). A representative
experiment is shown. (D) mORF74-mediated activation of Akt by KC and MIP-2. COS-7 cells were transfected with 2 g of cDNA encoding
mORF74 or 2 g of empty vector. Forty-eight hours after transfection, cells were stimulated with chemokine (107 M) (5 min), and phosphor-
ylation of Akt was determined by Western blot analysis using specific anti-phospho-Akt (P-Akt) antibodies. Phosphorylation was quantified by
chemiluminescence and corrected for total Akt (T-Akt) expression on stripped blots. Data are presented as fold increase over control values
(mock-transfected cells). A representative experiment is shown. All experiments were repeated at least two times.
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value (7.5 0.1) for mORF74 than human CXCL10/IP-10 (6.5
 0.4).
To determine whether mIP-10 could block agonist-induced
CRE inhibition, mORF74-transfected cells were incubated
with MIP-2, mIP-10, or MIP-2 and mIP-10 together. As shown
in Fig. 6C, mIP-10 reversed the inhibitory effect of MIP-2 on
forskolin-induced CRE activation, whereas mIP-10 alone had
no effect. Together, these findings support the hypothesis that
the inhibitory effects of mIP-10 on agonist-induced viral rep-
lication are through antagonism of mORF74.
DISCUSSION
Recently, several GPCRs encoded by various members of
the herpesvirus family have been shown to signal in a ligand-
independent fashion. Constitutive activity was shown for hu-
man cytomegalovirus-encoded US28 (7) and UL33 (46), mu-
rine cytomegalovirus-encoded M33 (46), rat cytomegalovirus-
encoded R33 (20) and HHV-8-encoded ORF74 (2). On the
basis of these observations, it is tempting to speculate that
constitutive activity is a general feature of vGPCRs and is
important for viral pathogenesis (39).
In view of the transforming potential of MHV-68-encoded
FIG. 5. Agonist-induced signaling of hORF74. (A) hORF74-medi-
ated activation of PLC. COS-7 cells were transfected with 2 g of
cDNA encoding hORF74 and incubated in the presence or absence of
PTX. Forty-eight hours after transfection, InsP accumulation was de-
termined in the presence or absence of chemokines (107 M).
(B) hORF74-mediated activation of NF-B. COS-7 cells were trans-
fected with 2 g of cDNA encoding hORF74 and incubated in the
presence or absence of PTX and chemokines (107 M). Forty-eight
hours after transfection, NF-B-driven luciferase expression was de-
termined. In both panels, a representative experiment performed in
triplicate is shown. Each experiment was repeated at least two times.
FIG. 6. Binding and antagonism of chemokines. (A) Displacement
of 125I-labeled CXCL1/GRO (125I-GRO) by agonists. COS-7 cells
were transfected with 5 g of cDNA encoding mORF74. Forty-eight
hours after transfection, 125I-labeled CXCL10/GRO binding was de-
termined in the presence of increasing concentrations of unlabeled
CXCL1/GRO, KC, or MIP-2. (B) Displacement of 125I-labeled
CXCL1/GRO (125I-GRO) by human and murine IP-10 (hIP-10 and
mIP-10, respectively). COS-7 cells were transfected with 5 g of cDNA
encoding mORF74. Forty-eight hours after transfection, 125I-labeled
CXCL10/GRO binding was determined in the presence of increasing
concentrations of unlabeled hCXCL10/IP-10 or mCXCL10/mIP-10.
(C) Antagonism of mIP-10 on mORF74. COS-7 cells were transfected
with 2 g of cDNA encoding mORF74 and 5 g of pTLNC-21CRE.
Eighteen hours after transfection, forskolin (105 M), MIP-2 (107
M), and mIP-10 (3 
 107 M) were added. Twenty-four hours after
transfection, CRE-driven luciferase expression was determined. In all
panels, a representative experiment performed in triplicate is shown.
Each experiment was repeated at least two times.
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mORF74 in NIH 3T3 cells (45), we compared the signaling
capacities of mORF74 with the highly constitutively active
vGPCR hORF74, encoded by HHV-8. Although HA-
mORF74 was expressed at the cell surface at the same level as
HA-hORF74 as determined in an ELISA, we could not detect
any degree of constitutive signaling by mORF74 to PLC, NF-
B, CRE, MAPK, or Akt in COS-7 cells. Also HA-mORF74
was not signaling constitutively, in contrast to HA-ORF74
(data not shown). However, we could detect ligand-dependent
activation of these pathways by mORF74. The human chemo-
kines CXCL1/GRO, CXCL8/IL-8, murine KC, and MIP-2,
which all contain the N-terminal motif glutamic acid-leucine-
arginine (ELR), inhibited forskolin-induced CRE activation.
Inhibition of CRE activation was sensitive to PTX, indicating
the involvement of Gi proteins. Similar to hORF74, only che-
mokines containing the ELR motif could activate mORF74.
The signaling capabilities of the murine chemokines KC and
MIP-2 were further investigated. Besides inhibiting CRE acti-
vation, KC and MIP-2 activated PLC, MAPK, Akt, and, to a
lesser extent, NF-B through mORF74. Activation of PLC by
KC and MIP-2 was also PTX sensitive and thus mediated
through G proteins of the Gi class. Cellular chemokine recep-
tors, including CXCR2 and CXCR3, activate PLC through a
similar classical PTX-sensitive mechanism in COS-7 cells upon
stimulation with CXCL8/IL-8 and CXCL11/IP-9, respectively
(data not shown). It is likely that this response is mediated by
the release of 	 subunits from Gi proteins which can stim-
ulate PLC isoforms, such as PLC-2, as was shown for example
for CXCR1 and CXCR2 (48).
mORF74 activated NF-B upon stimulation with KC and
MIP-2. However, compared to hORF74, mORF74-induced
NF-B activation was only moderate. It therefore was difficult
to address the involvement of Gi proteins in mORF74-medi-
ated NF-B activation. Of interest is a recent paper showing
that overexpression of NF-B inhibits gammaherpesvirus lytic
promoter activation and MHV-68 replication (5). Chemokine-
induced activation of NF-B by mORF74 might inhibit
MHV-68 lytic replication and therefore contribute to the es-
tablishment or maintenance of viral latency. This would be in
agreement with the expression of mORF74 during latency.
MHV-68 is used as a model for infection with human gam-
maherpesviruses, such as HHV-8, for which no well-defined in
vitro and in vivo assays are available. Aside from this, only
transgenic mouse models for hORF74-induced KS have been
developed (22, 26, 49). Therefore, we investigated whether
mORF74 uses signal transduction cascades similar to those
used by hORF74 upon activation with murine chemokines.
The G proteins through which mORF74 stimulates PLC are
different from those used by hORF74. Besides the lack of
constitutive signaling of mORF74, activation of PLC by KC or
MIP-2 through mORF74 is mediated by Gi proteins, in con-
trast to hORF74. It has previously been reported that KC does
not activate hORF74 in COS-7 cells (22), but we find a small
but significant stimulation of hORF74 by KC. Therefore, KC
can be considered a partial agonist for hORF74, which might
be of importance for the proper evaluation of transgenic
mouse models. We confirm the findings that hORF74 consti-
tutively activates NF-B (27, 36) in a Gi-dependent manner.
However, PTX did not fully inhibit constitutive activation of
NF-B, suggesting that constitutive activation of other G pro-
teins, e.g., Gq/11, contributes to the remaining signal (10, 37).
Interestingly, hORF74-mediated activation of NF-B by KC
and MIP-2 is completely independent from Gi activation in
COS-7 cells, in contrast to its constitutive activity. Our data
suggest that hORF74 constitutively couples to at least two
classes of G proteins in COS-7 cells, since hORF74 constitu-
tively activates PLC in a PTX-insensitive manner and NF-B in
a PTX-sensitive manner. Agonists induce a switch in G protein
coupling by hORF74 to a PTX-insensitive G protein.
hORF74 has been shown to induce a KS-like disease in
transgenic mice (26, 49). Using hORF74 mutants, it was con-
cluded that hORF74-mediated induction of the KS-like dis-
ease in transgenic mice requires not only constitutive signaling
but also modulation of constitutive activity by endogenous
chemokines (22). Our findings suggest that constitutive and
ligand-induced signaling of hORF74 may be two, at least
partly, separated phenomena due to preferential coupling to
different G proteins. This would explain why constitutive ac-
tivity alone is not sufficient to induce a KS-like disease in
transgenic mice. The lack of constitutive activity, the different
G protein preference, and the predominant expression of
mORF74 during latency, whereas hORF74 is mainly tran-
scribed during lytic infection, indicate that care must be taken
in the use of MHV-68 infection as a model system for
hORF74-mediated pathogenesis.
We identified the human chemokine 125I-labeled CXCL1/
GRO as a suitable and commercially available radioligand for
mORF74. KC and MIP-2 displaced 125I-labeled CXCL1/
GRO with high affinities. CXCL10/IP-10 and mIP-10, which
do not contain the ELR motif, were also able to displace
125I-labeled CXCL1/GRO, with the murine variant having
the highest affinity. Although mIP-10 does not inhibit forsko-
lin-induced cAMP formation, it could block the effect of
MIP-2. Together with our binding data, this identifies mIP-10
as an antagonist for mORF74, explaining the findings of Lee et
al., who found that mIP-10 could block KC-induced replication
of MHV-68 (24). Recently, increased mRNA expression of
mIP-10 was observed in the lungs of mice and moderate levels
of KC were found in bronchoalveolar lavage fluid specimens
after infection with MHV-68, both peaking at day 7 postinfec-
tion (35). Therefore, it is not unlikely that these chemokines
compete for binding to mORF74 in vivo.
In addition to PLC and NF-B, mORF74 stimulated both
p44/p42 MAPK and Akt upon addition of KC or MIP-2. p44/
p42 MAPK, known to be involved in cellular proliferation and
Akt, an inhibitor of apoptosis, are also activated by hORF74
(27, 38, 40). Interestingly, specific inhibitors of MEK and phos-
phatidylinositol 3-kinase, two kinases directly upstream of p44/
p42 MAPK and Akt, respectively, were able to block KC-
enhanced replication of MHV-68 in NIH 3T3 cells (24),
further corroborating the importance of these pathways in
mORF74-mediated viral replication. A recombinant MHV-68
with a disrupted mORF74 gene did not affect virus replication
in vitro or acute replication in vivo compared to WT MHV-68
(28). However, disruption of mORF74 appeared to lead in
time to a diminished efficiency of virus reactivation from peri-
toneal exudate cells. Also, Lee et al. reported no differences in
MHV-68 replication in vitro after disruption of mORF74 (24).
However, they found increased viral replication in NIH 3T3
cells after addition of KC or MIP-2 for WT MHV-68 but not
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for virus with disrupted mORF74. In addition, they also
showed impaired reactivation from latency for the mutant vi-
rus. These findings imply that mORF74 is involved in both viral
replication and reactivation from latency. Persistent replica-
tion during latency might be a direct consequence of reactiva-
tion from latency. Moreover, reactivation from latency and
replication during acute infection appear to be two distinct
processes (15). It is unclear in which stage of MHV-68 repli-
cation mORF74 is important. mORF74 might be involved in
suppression of lytic replication, maintenance of latency, and
avoiding detection by the immune response through activation
of NF-B (5). On the other hand, mORF74 was shown to be
involved in reactivation from latency and persistent replication,
thereby allowing the virus to infect other cells or spread
through the population. The activity of mORF74 can be reg-
ulated in a dose-dependent manner by chemokines and be
blocked by antagonists, thereby acting as an environmental
sensor. This suggests that the effect on viral replication might
be either way, depending on the strength and duration of the
chemokine signal.
Although mORF74 displays transforming activity in NIH
3T3 cells (45), we did not detect constitutive signaling activity
by mORF74. A possible explanation for the observed transfor-
mation of mORF74-expressing NIH 3T3 cells is activation of
mORF74 via autocrine secreted chemokines of NIH 3T3 cells,
such as KC (4). This might result in activation of transcription
factors and subsequent expression and secretion of factors,
such as chemokines, cytokines, and VEGF, which in turn can
activate mORF74 itself or cellular receptors, resulting in trans-
formation. An autocrine loop, however, would be in conflict
with the findings of Lee et al. (24) who found no differences in
virus growth between WT and mORF74 deletion mutants after
infection of NIH 3T3 cells in the absence of exogenously added
KC. One cannot exclude the possibility that mORF74 is con-
stitutively activating pathways other than the ones investigated
here and that these pathways are involved in transformation
but not virus growth. Also, for the human cytomegalovirus-
encoded US27, no constitutive activity could be detected (46),
and ECRF3/ORF74 from HVS does not appear to display
constitutive activity either, although it responds to chemokines
(1). Therefore, constitutive activity might not be a prominent
feature for all vGPCRs.
Taken together, we found that mORF74 does not display
constitutive activity in transiently transfected COS-7 cells. Nev-
ertheless, the murine chemokines KC and MIP-2 activate
NF-B and the kinase pathways p44/p42 MAPK and Akt.
Moreover, KC and MIP-2 activate PLC and inhibit forskolin-
induced CRE activation via G proteins of the Gi class. Murine
IP-10 acts as an antagonist on mORF74. The identification of
125I-labeled CXCL1/GRO as the first radioligand for
mORF74 will facilitate further research of this vGPCR.
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